TY - JOUR
T1 - Efficacy and tolerability of pregabalin in essential tremor
T2 - A randomized, double-blind, placebo-controlled, crossover trial
AU - Ferrara, Joseph M.
AU - Kenney, Christopher
AU - Davidson, Anthony L.
AU - Shinawi, Lina
AU - Kissel, Abigail M.
AU - Jankovic, Joseph
N1 - Funding Information:
This investigator-initiated study was supported by a grant from Pfizer, Inc.
PY - 2009/10/15
Y1 - 2009/10/15
N2 - We performed a double-blind, crossover-design study to assess the tolerability and efficacy of pregabalin (PGB) in patients with essential tremor (ET). Twenty patients (11 women; mean age of 62.2 ± 12.7 years, mean ET duration of 25.5 ± 14.9 years) with ET were randomized for treatment with PGB (150-600 mg/day) or placebo, titrated over 6 weeks. Identical assessments of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (primary endpoint), Clinical Global Impression of Change (CGI-C), Quality of Life in Essential Tremor Questionnaire (QUEST), Hamilton Anxiety Scale (HAM-A), and a sleep hygiene questionnaire (HD-16) were made at the baseline, at the end of treatment periods for both drug and placebo, and following the 2-week washout period preceding crossover. We found no improvement in any of the TRS measures and a statistically significant worsening of QUEST scores while patients were taking PGB. Adverse events were similar in frequency to previously published studies of PGB, the most common being drowsiness and dizziness.
AB - We performed a double-blind, crossover-design study to assess the tolerability and efficacy of pregabalin (PGB) in patients with essential tremor (ET). Twenty patients (11 women; mean age of 62.2 ± 12.7 years, mean ET duration of 25.5 ± 14.9 years) with ET were randomized for treatment with PGB (150-600 mg/day) or placebo, titrated over 6 weeks. Identical assessments of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (primary endpoint), Clinical Global Impression of Change (CGI-C), Quality of Life in Essential Tremor Questionnaire (QUEST), Hamilton Anxiety Scale (HAM-A), and a sleep hygiene questionnaire (HD-16) were made at the baseline, at the end of treatment periods for both drug and placebo, and following the 2-week washout period preceding crossover. We found no improvement in any of the TRS measures and a statistically significant worsening of QUEST scores while patients were taking PGB. Adverse events were similar in frequency to previously published studies of PGB, the most common being drowsiness and dizziness.
KW - Essential tremor
KW - Fahn-Tolosa-Marin Tremor Rating Scale (TRS)
KW - Pregabalin
KW - Quality of Life in Essential Tremor Questionnaire (QUEST)
UR - http://www.scopus.com/inward/record.url?scp=69749117734&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2009.06.044
DO - 10.1016/j.jns.2009.06.044
M3 - Article
C2 - 19631949
AN - SCOPUS:69749117734
SN - 0022-510X
VL - 285
SP - 195
EP - 197
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
IS - 1-2
ER -